Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Key Highlights
- ➤Foundayo 17.2 mg delivered 1.5% greater weight loss versus oral semaglutide 25 mg at 52 weeks
- ➤Foundayo 17.2 mg lowered A1C 0.3% more than oral semaglutide 25 mg at 52 weeks
- ➤Foundayo 17.2 mg showed 1.5% to 2.4% greater weight loss across analyses
- ➤Foundayo 17.2 mg showed 0.3% to 0.6% greater A1C reduction across analyses
- ➤ACHIEVE-3 Foundayo 17.2 mg cut A1C 2.2% versus 1.4% for oral semaglutide 14 mg
Expert Statements
Deborah Horn, D.O., director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston
“Having data to help us compare available medications provides clinicians the opportunity to make informed treatment choices that fit each patient's needs.”
Rachel Batterham, OBE, MBBS, Ph.D., FRCP, senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health
“Head-to-head trials ultimately provide the best comparison of two medicines, but when we don't yet have those data, then other approaches can provide informative data points.”
Rachel Batterham, OBE, MBBS, Ph.D., FRCP, senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health
“Results from this indirect treatment comparison suggest that Foundayo may deliver A1C and weight lowering that is similar to the 25 mg dose of oral semaglutide.”
Rachel Batterham, OBE, MBBS, Ph.D., FRCP, senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health
“These results, paired with simple administration free of fasting or water restrictions, are what make Foundayo a potentially foundational therapy for adults managing type 2 diabetes around the world.”
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison PR Newswire
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks
Get started
Create a free account to read the full story.